Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The megalithic site of Gunung Padang in the highlands of western Java was constructed some 2,000 years ago over the course of several generations. Similar stone monuments are found across the ...

Want to know how the Hogwarts Legacy sorting hat works? The sorting process is one of the most important factors as you start your new life at the Wizarding School of Witchcraft and Wizardry. Fans of ...

Parallel programming exploits the capabilities of multicore systems by dividing computational tasks into concurrently executed subtasks. This approach is fundamental to maximising performance and ...

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. A merger combines two companies into one.